TTC16

Across TCGA pan-cancer cohorts, TTC16 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TTC16 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TTC16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC16 expression acts as an unfavorable survival marker.

HNSC, COAD, and LIHC are the cancer types where TTC16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.141	0.628	<.001	24	view →
COAD	DFS	Median	All	0.216	0.694	.001	18	view →
LIHC	OS	Median	All	0.059	0.783	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.148	0.594	.040	3	view →
SKCM	DFS	Median	IV	0.016	0.541	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TTC16–HNSC (DFS)

Open the HNSC breakdown →